Citius Pharmaceuticals unit shares LYMPHIR quality-of-life data from Study 302
Citius Pharmaceuticals said its majority-owned subsidiary, Citius Oncology, issued a press release on November 4, 2026, presenting health-related quality of life results from pivotal Study 302 of LYMPHIR in relapsed or refractory cutaneous T-cell lymphoma. The data were presented at the EORTC-CLTG 2026 Annual Meeting in Berlin, held October 8–10, 2026. The filing states the quality of life analyses were exploratory and descriptive, with no formal statistical comparisons, and it contains no financial results or guidance.
Key points
- Responders (n=25) in the primary analysis set showed mean Skindex-29 Total Score changes from -5.38 to -13.69 points, where lower scores indicate better quality of life.
- Responders' FACT-G Total Score change at end of treatment was +3.21, compared with -2.28 for non-responders.
- Among 41 patients with a baseline itch score of 20 mm or greater, 13 (32%; 95% CI, 18.1–48.1) achieved a clinically meaningful itch improvement.
- Citius Oncology is partnering with the Cutaneous Lymphoma Foundation on a Quality of Life Workshop scheduled for November 2026.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.